Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2014
At a glance
- Drugs Levosimendan (Primary)
- Indications Decompensated heart failure; Myocardial infarction
- Focus Biomarker; Pharmacodynamics
- Acronyms LEAF
- 10 Jun 2017 Biomarkers information updated
- 29 Aug 2012 Primary endpoint 'Wall-motion-score' has been met according to results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
- 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.